Behavioral and pharmacologic therapies for obesity
- 3 August 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Endocrinology
- Vol. 6 (10), 578-588
- https://doi.org/10.1038/nrendo.2010.121
Abstract
A comprehensive program of lifestyle modification, comprised of diet, physical activity and behavior therapy, is the cornerstone of treatment for individuals with overweight or obesity. This article reviews options for lifestyle modification and pharmacotherapy for obesity and concludes with an examination of genes that contribute to obesity, which may yield new targets for pharmacologic intervention and ultimately gene therapy. This article reviews novel developments in the behavioral and pharmacologic treatment of obesity and explores the potential contribution of genomics research to weight control. A comprehensive program of lifestyle modification, comprised of diet, physical activity and behavior therapy, induces a mean loss of 7–10% of initial weight in individuals with obesity. Two trials demonstrated that weight loss of this magnitude, combined with increased physical activity, substantially reduced the risk of developing type 2 diabetes mellitus in individuals with impaired glucose tolerance. A third trial is now investigating whether lifestyle intervention will reduce cardiovascular morbidity and mortality in overweight individuals who already have diabetes mellitus. Pharmacotherapy is recommended, in some patients, as an adjunct to lifestyle modification. Two medications—orlistat and sibutramine—are currently approved in the US for long-term weight loss. Both are efficacious when combined with lifestyle modification, although health concerns have been raised about the use of sibutramine. Several novel combination therapies, which target multiple hypothalamic pathways that regulate appetite and body weight, are currently under investigation. Genomic studies provide further evidence for the role of these pathways in the regulation of body weight. Identification of new genes controlling satiety and energy expenditure may yield valuable clues for the development of novel pharmacologic treatments.Keywords
This publication has 112 references indexed in Scilit:
- Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity PharmacotherapyObesity, 2009
- Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and CarbohydratesThe New England Journal of Medicine, 2009
- Six new loci associated with body mass index highlight a neuronal influence on body weight regulationNature Genetics, 2008
- Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat DietThe New England Journal of Medicine, 2008
- Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studiesProceedings of the National Academy of Sciences of the United States of America, 2008
- Common variants near MC4R are associated with fat mass, weight and risk of obesityNature Genetics, 2008
- A Common Variant in the FTO Gene Is Associated with Body Mass Index and Predisposes to Childhood and Adult ObesityScience, 2007
- Central nervous system control of food intake and body weightNature, 2006
- A Randomized Trial Comparing Human e-Mail Counseling, Computer-Automated Tailored Counseling, and No Counseling in an Internet Weight Loss ProgramArchives of Internal Medicine, 2006
- The Look AHEAD Study: A Description of the Lifestyle Intervention and the Evidence Supporting ItObesity, 2006